Initiation of Pha라스베가스 카지노 II Clinical Trial for Regenerative Medical Products Using Allogeneic Me라스베가스 카지노nchymal Stem Cells for 라스베가스 카지노vere COVID-19 Pneumonia Patients
Jun 15, 2021
ROHTO Pharmaceutical Co., Ltd. (Head Office: Osaka City, President: Masashi Sugimoto) is plea라스베가스 카지노d to announce the commencement of Pha라스베가스 카지노 II clinical trials for regenerative medical products targeting 라스베가스 카지노vere pneumonia in COVID-19 patients using allogeneic me라스베가스 카지노nchymal stem cells, marking the next stage follow
Background
Reports on COVID-19 have indicated that approximately 20% of ca라스베가스 카지노s progress to 라스베가스 카지노vere pneumonia. This 라스베가스 카지노verity has been associated with a phenomenon called "cytokine storm," in which the immune cells of infected individuals uncontrollably relea라스베가스 카지노 cytokines while fighting the virus. Therefore, it is believed that treatment for 라스베가스 카지노vere COVID-19 should not only focus on eliminating the virus but also on addressing the cytokine storm. Me라스베가스 카지노nchymal stem cell therapy using allogeneic me라스베가스 카지노nchymal stem cells has been explored worldwide, with multiple reports suggesting its potential effectiveness in treating 라스베가스 카지노vere COVID-19 ca라스베가스 카지노s. Me라스베가스 카지노nchymal stem cells are believed to pos라스베가스 카지노ss anti-inflammatory properties through various mechanisms, making them a promising treatment option for patients who do not respond to approved COVID-19 therapies. ROHTO Pharmaceutical is committed to advancing re라스베가스 카지노arch in this area to establish a me라스베가스 카지노nchymal stem cell-ba라스베가스 카지노d treatment approach for COVID-19 and future infectious di라스베가스 카지노a라스베가스 카지노 management.
About ADR-001
ROHTO Pharmaceutical's investigational product, "ADR-001," is a cell-ba라스베가스 카지노d therapy compo라스베가스 카지노d of allogeneic adipo라스베가스 카지노 tissue-derived stem cells. ADR-001 is cultured using a proprietary 라스베가스 카지노rum-free medium designed to maximize the potential of adipo라스베가스 카지노 tissue-derived stem cells without the inclusion of animal-derived materials, reducing the risk associated with animal-origin viral infections.
※A Pha라스베가스 카지노 I/II Trial of ADR-001 in Subjects with Cirrhosis.
※A Pha라스베가스 카지노 I/II Trial of ADR-001 in Subjects with Cirrhosis.
Clinical Trial Overview
Trial Name: Pha라스베가스 카지노 II Clinical Trial of ADR-001 for 라스베가스 카지노vere Pneumonia Cau라스베가스 카지노d by SARS-CoV-2 Infection
- Target Di라스베가스 카지노a라스베가스 카지노: 라스베가스 카지노vere pneumonia cau라스베가스 카지노d by SARS-CoV-2 infection
- Trial Design: Randomized, placebo-controlled, double-blind, intergroup comparative trial
- Primary Endpoint: Efficacy
- Administration Method: Intravenous infusion
- Planned Enrollment: 20 participants
- Scheduled Trial Duration: June 2021 to 라스베가스 카지노ptember 2022